Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangsu Recbio Technology Co., Ltd.
江蘇瑞科生物技術股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 02179)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2025 ANNUAL REPORT AND THE 2026 INTERIM REPORT

Reference is made to the annual report of Jiangsu Recbio Technology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") for the year ended December 31, 2025 (the "**2025 Annual Report**") and the interim report for the six months ended June 30, 2026 (the "**2026 Interim Report**"). Unless otherwise specified, terms used in this announcement shall have the same meanings as those defined in the 2025 Annual Report and the 2026 Interim Report.

The Board of Directors (the "**Board**") of the Company hereby provides supplementary information in relation to REC603 ("**REC603**"), a recombinant HPV 9-valent vaccine candidate and a Core Product of the Company under Chapter 18A of the Listing Rules.

REC603 obtained IND approval from the National Medical Products Administration (NMPA) in July 2018. According to the product registration classification and written communications with the Center for Drug Evaluation of the NMPA, we were permitted to directly conduct the phase III clinical trial in China after obtaining the phase I clinical data. Currently, REC603 is in a pivotal stage of the phase III clinical trial in China. We are conducting regular follow-up visits in accordance with the clinical protocol, and as of December 31, 2025 and June 30, 2026, we had completed the 48th month visit and observation and the 54th month visit and observation, respectively, and we are currently conducting the 60th month visit and observation. As of the date of this announcement, due to the extended time required for the collection of clinical endpoint cases, the Company has not yet completed the submission of the marketing application for REC603 in accordance with the expected timetable. The pivotal efficacy trial of the Phase III clinical trial of REC603 in China, with pathologically confirmed CIN2+ (including CIN 2/3, adenocarcinoma in situ (AIS) and invasive cervical cancer), VIN2+ (including VIN 2/3 and vulvar cancer) and VaIN2+ (including VaIN 2/3 and vaginal cancer) associated with infection by the high-risk HPV types contained in the investigational vaccine as the primary efficacy endpoint, requires the accrual of a pre-specified number of endpoint cases before an interim analysis may be conducted. In recent years, the HPV-related epidemiological landscape in China has undergone significant changes. With the extensive implementation of HPV vaccination programmes for age-eligible females (HPV vaccines have been incorporated into the National Immunisation Programme) and the continuing increase in vaccination coverage, the infection rates and transmission levels of specific HPV types among age-eligible female populations in the trial implementation regions have decreased as compared with the epidemiological assumptions made at the time of the trial design. Meanwhile, driven by national policies on the integrated prevention and control of cervical cancer, the coverage of cervical cancer screening has continued to increase, enabling earlier detection and timely treatment of precancerous lesions, thereby correspondingly reducing the incidence of new high-grade lesions in the population. Affected by the above-mentioned epidemiological changes, the actual accrual rate of endpoint cases for certain types within the trial population was lower than originally anticipated. Accordingly, the period for case collection and follow-up needs to be extended in order to accrue a sufficient number of endpoint cases and ensure the statistical significance of the interim analysis and the reliability of the results.

In order to accelerate the research and development and registration progress of REC603, the Company has completed the adjustment of the core management team of the HPV industrialisation segment, and will strengthen the comprehensive management of the entire process including clinical execution, pharmaceutical research and registration application, thereby ensuring the efficient advancement of all stages. The Company will coordinate and advance the submission of the product marketing application based on the actual progress of clinical follow-ups, the progress of process validation, and the ongoing communications with the regulatory authorities. Taking into account the development status as of December 31, 2025 and June 30, 2026, and subject to the uncertainties further explained below, the Group expects that, upon successful development, REC603 will be commercialised and launched in the market between 2029 and 2030. Save as disclosed above, all other information in the 2025 Annual Report and the 2026 Interim Report remains unchanged.

The research and development, filing and commercialization of vaccines are subject to a number of uncertainties, including but not limited to, the progress of clinical visits and sample collection from key cases, results of process validation, continuity of stock solution production, scope of quality standards studies, outcomes of communications with the CDE, the NDA review cycle, on-site inspections, market competition, national immunization programs and centralized procurement policies, and price competition.

We cannot guarantee that we will ultimately develop or market REC603 successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Jiangsu Recbio Technology Co., Ltd.
Mr. XU Haoyu
Chairman

Jiangsu Province, the PRC, November 9, 2026

As at the date of this announcement, the Board comprises Mr. XU Haoyu as the chairman of the Board and a non-executive director, Dr. LIU Yong and Ms. WANG Jing as executive directors, Dr. WANG Ruwei, Dr. ZHANG Jiaxin, Dr. ZHOU Hongbin and Mr. HU Houwei as non-executive directors, and Dr. XIA Lijun, Mr. LIANG Guodong, Professor GAO Feng and Professor YUEN Ming Fai as independent non-executive directors.